Analysts Set Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Target Price at $44.29

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $43.75.

EYPT has been the topic of a number of research analyst reports. Cantor Fitzgerald began coverage on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, July 8th. They set an “overweight” rating and a $47.00 price objective on the stock. Chardan Capital increased their target price on shares of Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Guggenheim reissued a “buy” rating and set a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 price target on the stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in EYPT. Cyndeo Wealth Partners LLC raised its stake in Eyepoint Pharmaceuticals by 3.4% during the 4th quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company’s stock valued at $420,000 after purchasing an additional 760 shares during the last quarter. California State Teachers Retirement System grew its position in Eyepoint Pharmaceuticals by 20.6% in the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the last quarter. RWC Asset Management LLP grew its position in Eyepoint Pharmaceuticals by 6.4% in the 4th quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after purchasing an additional 1,040 shares during the last quarter. MCF Advisors LLC increased its holdings in shares of Eyepoint Pharmaceuticals by 8.3% during the 4th quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock worth $273,000 after purchasing an additional 1,149 shares during the period. Finally, Raymond James Financial Inc. raised its position in shares of Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after buying an additional 1,177 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Trading Down 4.8%

Shares of Eyepoint Pharmaceuticals stock opened at $12.66 on Thursday. Eyepoint Pharmaceuticals has a 1 year low of $9.40 and a 1 year high of $19.11. The company has a market cap of $1.06 billion, a P/E ratio of -3.62 and a beta of 1.73. The stock has a 50-day moving average price of $13.23 and a 200 day moving average price of $14.18.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.79) by ($0.20). The business had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. On average, equities analysts forecast that Eyepoint Pharmaceuticals will post -3.31 earnings per share for the current fiscal year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.